Kazia concludes first stage of Phase I advanced cancer treatment trial [Yahoo! Finance]
Kazia Therapeutics Limited - American Depositary Shares (KZIA)
US:NASDAQ Investor Relations:
kaziatherapeutics.com
Company Research
Source: Yahoo! Finance
The trial's Safety Review Team (SRT) has confirmed that the study has met its primary and secondary objectives for this stage. The dose-finding, open-label study is focused on evaluating the safety, tolerability, and pharmacokinetics (PK) of EVT801 in subjects with advanced or metastatic solid tumours who are not responsive to standard treatment or for whom no standard therapy is available. It enrolled patients with eleven different types of advanced or metastatic solid tumours, including ovarian cancer, which was the most prevalent among the participants. The primary objective of the trial was to assess the safety and tolerability of EVT801 as well as to establish the maximal tolerated dose (MTD) and / or a recommended Phase II dose (RP2D) of EVT801 daily dose. Secondary objectives included characterising the PK profile of the oral capsule formulation of EVT80, identifying active metabolites of EVT801 in plasma, and detecting initial anti-tumour activity. To validate the t
Show less
Read more
Impact Snapshot
Event Time:
KZIA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KZIA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KZIA alerts
High impacting Kazia Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
KZIA
News
- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS [Yahoo! Finance]Yahoo! Finance
- KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTSPR Newswire
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases [Yahoo! Finance]Yahoo! Finance
- Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseasesPR Newswire
- Kazia announces presentation of new data at AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
KZIA
Sec Filings
- 5/17/24 - Form 424B3
- 5/17/24 - Form 6-K
- 5/1/24 - Form 424B3
- KZIA's page on the SEC website